Retatrutide 40mg 99% pure — 16-24 week mega-cycle triple agonist

Zoom

5mg38,00 €10mg60,00 €20mg105,00 €30mg145,00 €40mg180,00 €

180,00 €

Tax included • Free delivery from 99€

+9,00 € in loyalty cashback, with an account. Create my account

23 in stock · Ships from France

Next dispatch: Tuesday, September 8

Subscription

162,00 €-10 %instead of 180,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

What the parcel contains

One sealed vial of Retatrutide 40mg, lyophilised, without individual labelling.

What you also need

Bacteriostatic water for reconstitution and 1 ml precision syringes graduated in 100 units, sold separately. The vial alone cannot be used as is.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Cartouches 3 mlx59,90 €

Aiguilles Stylo Injecteurx1010,90 €

Retatrutide 40mg is the mega-cycle format reserved for advanced research protocols over 16-24 weeks at 12mg target dose. One vial covers 3.33 weeks at 12mg, 4 weeks at 10mg, 5 weeks at 8mg. Volumetric density maximally exploits the post-reconstitution stability window: at 12mg target dose, 3.33 weeks consume 80% of the 28-day period, which remains comfortable but demands rigorous discipline on cold-chain management and fridge-exit minimization.

Operational economics: for a 24-week cycle at 12mg/week, total need 288mg. In 40mg format, 7.2 reconstitutions needed, i.e., 8 vials. Vs 30mg format: 9.6 reconstitutions (10 vials). Vs 20mg: 14.4 (15 vials). Vs 10mg: 28.8 (29 vials). 40mg is thus the most economical format in terms of handling for long cycles, but demands stricter logistical organization (precise schedule, dated labeling, temperature monitoring).

Reconstituted at 4 mL (10 mg/mL), it delivers 12mg in 1.2 mL and 10mg in 1 mL. At 8 mL (5 mg/mL), it delivers 12mg in 2.4 mL (high volume, 2-site splitting recommended). 10 mg/mL is the norm for this format: a 40mg vial covers exactly 3 doses of 12mg + 4mg residual. Optimized sequence: every 4th week, reconstitute a new vial while preserving 4mg residual from the previous, usable as intercalated injection or discarded if degradation suspected. For sophisticated researchers, precise residual-use planning can extend the vial-covered duration to 3.33 full weeks.

Science

01
Mechanism of action

Retatrutide is the first triple incretin-mimetic agonist to reach phase II/III clinical development. Its sequence combines three activities: GLP-1R, GIPR, and GCGR (glucagon receptor), a design that unites in a single molecule the three main metabolic levers of energy regulation. Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days. The affinity profile is calibrated for triple balance: full agonist at GIPR, full agonist at GLP-1R, partial agonist at GCGR, preserving glycemia while exploiting glucagon thermogenic benefits.

The GCGR arm is retatrutide's signature. Hepatic glucagon increases gluconeogenesis and lipolysis via PKA/CREB activation, stimulates brown adipose tissue thermogenesis, and reduces hepatic triglyceride accumulation. This activity partly antagonizes the GIP lipogenic effect and translates clinically into weight loss exceeding tirzepatide's. Tuning the GCGR / GLP-1 + GIP affinity ratio is critical: too much GCGR would trigger hyperglycemia; too little would cancel the thermogenic benefit. Retatrutide was optimized to maximize brown adipose activity without net glycemic disturbance, thanks to the combined glucose-normalizing effect of the GLP-1/GIP incretins.

Additive mechanisms: central activation of GLP-1R / GIPR hypothalamic satiety circuits, slowed gastric emptying, amplified glucose-dependent insulin secretion, direct adipocyte lipolysis via GCGR, brown thermogenesis via UCP1, and increased hepatic lipid oxidation. Obese mouse models (Coskun 2022) show basal energy expenditure +8-12% vs vehicle, a major contributor to the magnitude of weight loss observed in phase II clinical trials.

Pharmacokinetics: approximate terminal half-life 6 days, Cmax at 40-48 hours post-injection, steady-state in 4-5 weeks. Proteolytic clearance (no CYP450), no major pharmacokinetic interactions expected. Subcutaneous bioavailability is nearly complete thanks to albumin binding conferred by the C20 chain. Weekly administration standardizes pharmacokinetics, simplifies protocols, and smooths plasma concentrations — conditions favorable for reproducible cohort studies.

In exploratory research, retatrutide represents the most ambitious incretin agent currently available. Its signaling complexity (triple agonism) imposes heightened methodological vigilance: systematic glycemic monitoring to detect any paradoxical hyperglycemia linked to the glucagon arm, regular hepatic panel given the lipolytic effect, and lean mass tracking to quantify the share of weight loss linked to muscle depletion under severe caloric restriction.

Clinical data

02Clinical studies

Clinical data on retatrutide are still recent but spectacular. The pivotal phase II obesity trial Jastreboff 2023 NEJM (Retatrutide Phase 2 Obesity Trial) tested 1/4/8/12mg weekly in 338 obese non-diabetic adults over 48 weeks. Mean weight loss: -8.7% (1mg), -17.1% (4mg), -22.8% (8mg), -24.2% (12mg) vs -2.1% placebo. At 12mg, 92% of participants lost >= 5%, 75% >= 15%, 56% >= 20%, and 26% lost >= 25%. These figures are the highest ever published for an anti-obesity pharmacological agent and directly rival sleeve gastrectomy bariatric surgery (typically -25% at 1 year).

Phase II diabetes study Rosenstock 2023 Lancet: 281 T2D patients over 36 weeks with doses 0.5/4/8/12mg. HbA1c: -2.02% at 12mg vs -0.01% placebo; weight loss -16.94% vs -3.0% placebo at 12mg. Retatrutide demonstrated an effect equivalent or superior to the best GLP-1 mono-agonists on diabetes while producing markedly stronger weight loss.

Phase II hepatic steatosis study Sanyal 2024 Lancet: retatrutide 5-10mg weekly in 98 patients with MASLD and obesity, over 48 weeks. Hepatic fat fraction reduction: -57.0% (5mg), -81.4% (10mg) vs -0.3% placebo. At 10mg, 85% of patients reached hepatic fat fraction < 5% (resolution threshold), 74% had >= 30% reduction. These results exceed those of any other pharmacological agent tested on MASLD, including tirzepatide in SYNERGY-NASH.

Phase III TRIUMPH trials are ongoing. TRIUMPH-1 (adult obesity, n=2250), TRIUMPH-2 (obesity with comorbidities), TRIUMPH-3 (type 2 diabetes + obesity), TRIUMPH-4 (MASH with fibrosis), TRIUMPH-6 (sleep/OSA): results expected 2025-2027. The program was designed to demonstrate broad superiority vs tirzepatide (direct comparator in certain arms) on weight loss, metabolic improvement, hepatic steatosis, and sleep apnea.

Tolerance profile: in phase II trials, gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) are frequent but mostly mild-to-moderate and concentrated in the early titration weeks. Adverse-event discontinuation rate was 6-16% depending on dose. Two signals deserve vigilance: mean heart rate increase of 3-7 bpm (similar to tirzepatide, likely linked to the GLP-1 arm), and modest ALT elevation in some patients (likely linked to GCGR-induced hepatic lipolysis). Retatrutide did not produce significant hypoglycemia in non-diabetics, confirming that the glucagon arm is properly balanced by the incretin arm.

In research these references structure protocols. The standard phase II titration was: 2mg W1-4, 4mg W5-8, 8mg W9-12, 12mg W13+ (progression by 4mg steps every 4 weeks). Researchers seeking to reproduce Jastreboff 2023 conditions use this schema as reference. Phase III trials test extended plateaus up to 16mg in certain arms, reflecting the possibility of an unsaturated dose-response even at 12mg.

1
ObésitéTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023
2
Diabète type 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
Rosenstock J, Frías J, Jastreboff AM, et al. · The Lancet · 2023

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Jastreboff 2023 12mg plateau over 16-24 weeks or TRIUMPH-like extended long-cycle.

Option A — 12mg target mega-cycle plateau (3.33 weeks per vial): reconstitute 40mg with 4 mL (10 mg/mL). Draw 1.2 mL (120 units on 2 mL syringe) delivers 12mg. One vial = 3 full doses + 4mg residual. 4-weeks-per-vial sequence using residual in W4 (draw 0.4 mL = 4mg + 0.8 mL residual = 8mg from next vial reconstituted at D21). 16-week cycle = 4 vials. 24-week cycle = 6-7 vials. 36-week cycle = 9-10 vials.

Option B — Sanyal 10mg mega-cycle plateau (4 weeks per vial): reconstitute 40mg with 4 mL (10 mg/mL). Draw 1 mL (100 units) delivers 10mg. One vial = 4 exact doses, 0 residual. 48-week cycle (Sanyal 2024 Lancet hepatic steatosis reproduction) = 12 vials of 40mg. Logistical optimum for extended hepatic steatosis protocols.

Option C — 8mg W9-12 plateau (5 weeks per vial, stability caution): reconstitute 40mg with 4 mL (10 mg/mL). Draw 0.8 mL (80 units) delivers 8mg. One vial = 5 exact doses. This option approaches the 28-day post-reconstitution limit at cycle end (D35 > 28d = >10% degradation), reserve for researchers with rigorous temperature monitoring. Alternative: 4 doses (4 weeks = D28 limit) + 8mg residual discarded.

Option D — 15mg exploratory plateau (2.67 weeks per vial): reconstitute 40mg with 4 mL (10 mg/mL). Draw 1.5 mL (150 units) delivers 15mg. One vial = 2 doses + 10mg residual (0.67 additional dose). Sequence: W1-2 vial 1 (2 doses + 10mg residual), W3 combination 10mg residual + vial 2 = 15mg dose, and so on. TRIUMPH phase III protocols with enhanced hepatic monitoring.

Option E — 36-week ultra-mega-cycle at target dose: reconstitute 40mg with 4 mL (10 mg/mL). At 12mg/w, one vial = 3 doses + 4mg residual. 36 weeks / 3 doses = 12 vials if residuals discarded, or 10 vials if residuals combined. Organize a visual planning displayed in the laboratory area: vial N opening date, vial N+1 scheduled opening date (D+21), syringe arrangement, needle arrangement, wipe arrangement. This logistical preparation is the limiting factor on ultra-long cycles, not the molecule.

Mega-cycle monitoring: metabolic + hepatic + renal panel every 4-6 weeks (more frequent than standard cycle due to high cumulative exposure). Baseline cardiac echo + at 6 months. Hepatic echo / MRI PDFF at W0, W12, W24, W36. Bone densitometry at W0 and W36 if bone loss suspected with massive weight loss. Daily adverse-event journal for the first 4 weeks then weekly. Monthly standardized photos. Psychological follow-up if notable eating-behavior changes.

Reconstitution for this format (40 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
2 ml	20 mg/ml	10 UI = 2 mg
4 ml	10 mg/ml	10 UI = 1 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Lyophilized retatrutide stores up to 24 months between 2 and 8 degC, protected from light, in its original borosilicate vial sealed under inert atmosphere. The peptide is stable in solid form; degradation pathways become operational only after solubilization. Extended stocks can tolerate -20 degC (deep freeze) without documented integrity loss, provided freeze-thaw cycles are avoided as they introduce mechanical stress on tertiary structure.

After reconstitution with bacteriostatic water (0.9% benzyl alcohol), the solution stores for 21-28 days at 2-8 degC, protected from light. The C20 diacid chain is more hydrophobic than semaglutide's (C18) and tirzepatide's, slightly slowing degradation but increasing oligomerization propensity if the solution undergoes agitation or shear. Dominant degradation pathways: methionine oxidation (specifically Met30), asparagine deamidation (Asn25, Asn35) pH-sensitive, aspartate isomerization, and oligomerization/fibrillation via the C20 lipid anchor. After 28 refrigerated days, typically expect 5-10% activity loss, acceptable for most research protocols.

Operational recommendations: (1) handle the reconstituted vial with powder-free nitrile gloves to avoid surface contaminants that would catalyze degradation; (2) never vortex or shake, prefer gentle rotation with the vial tilted at 45 degrees until complete dissolution (typically 30-60 seconds); (3) if a precipitate persists after 5 minutes, warm gently to 25 degC (hand, never > 30 degC); (4) post-reconstitution storage must be a constant 2-8 degC, ideally low in the fridge (thermally most stable area), in a peptide-dedicated compartment (no contact with food or other volatile products).

For long-duration research cycles, choosing the right format is the first line of defense against degradation. A 12-week cycle at 12mg/week requires 144mg. In 5mg format that means 29 reconstitutions; in 10mg, 15; in 20mg, 8; in 30mg, 5; in 40mg, 4 reconstitutions. Each reconstitution reduction divides by the same factor the contamination risk, operator time, and consumable costs (bacteriostatic water, sterile syringes, needles, wipes). Golden rule: choose the format whose quantity divided by the weekly dose yields between 2 and 4 weeks of coverage.

01Why is retatrutide called a "triple agonist" and what does it change in practice?

Retatrutide simultaneously activates three receptors: GLP-1R, GIPR, and GCGR (glucagon). Mono-agonists (semaglutide) activate only GLP-1R; dual agonists (tirzepatide) add GIPR. Retatrutide pushes the architecture one step further with the glucagon arm, adding brown adipose tissue thermogenesis, direct hepatic lipolysis, and massive intrahepatic triglyceride reduction. Clinical consequence (Jastreboff 2023 NEJM): mean weight loss -24.2% at 12mg/48w, vs -20.9% for tirzepatide (SURMOUNT-1). The GCGR agonism is calibrated as partial to avoid triggering hyperglycemia, balanced by the GLP-1/GIP glucose-normalizing effect.

02What volume of bacteriostatic water should be used to reconstitute a retatrutide vial?

Volume depends on format and target weekly dose. For 5mg, 1 mL = 5 mg/mL (5mg dose in 1 mL). For 10mg, 2 mL = 5 mg/mL, or 1 mL = 10 mg/mL. For 15mg, 3 mL = 5 mg/mL, or 1.5 mL = 10 mg/mL. For 20mg, 4 mL = 5 mg/mL, or 2 mL = 10 mg/mL. For 30mg, 3 mL = 10 mg/mL (10mg dose in 1 mL), or 6 mL = 5 mg/mL. For 40mg, 4 mL = 10 mg/mL. Practical rule: pick a concentration yielding 100 units (1 mL) on a U100 syringe for the target dose, maximizing measurement precision.

03How long can reconstituted retatrutide be stored, and what signs indicate degradation?

21-28 days at 2-8 degC protected from light. The benzyl alcohol in bacteriostatic water preserves microbial sterility but not chemical integrity. Degradation pathways: Met30 oxidation, Asn25/35 deamidation, oligomerization via C20 diacid chain (more hydrophobic than semaglutide's C18, therefore more prone to protein interactions). Visual signs: cloudiness, precipitate, crystals, yellow or amber color, flocculation on gentle swirl. A healthy solution is clear and colorless. If in doubt, discard and reconstitute. Expected activity loss 5-10% after 28 days. For long cycles, plan reconstitutions to minimize time since reconstitution.

04Why must retatrutide be titrated progressively, and according to what schedule?

Titration is imposed by gastrointestinal tolerance, aggravated by the glucagon arm's additional effect on motility and glycemia. At full dose from start, 60-80% of subjects experience severe nausea, vomiting, and fatigue; early discontinuation climbs >20%. The Jastreboff 2023 NEJM protocol requires: 2mg weekly W1-4, 4mg W5-8, 8mg W9-12, 12mg W13+ (4mg steps every 4 weeks). For exploratory protocols targeting > 12mg, extend titration: 16mg W17-20, 20mg W21+ (4mg steps). For ultra-high doses (30-40mg), extend further with 5mg steps. Titration preserves adherence and allows gastrointestinal receptor desensitization.

05What are key drug interactions and contraindications for retatrutide?

Absolute contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome (preclinical rodent signal on C-cells, precautionary principle), active pancreatitis, severe hepatic insufficiency (the glucagon arm increases hepatic lipolysis and may worsen compromised function). Interactions: slowed gastric emptying alters absorption of narrow-therapeutic-window oral drugs (warfarin, digoxin, levothyroxine, immunosuppressants). Oral contraceptives: efficacy potentially reduced for 4 weeks after each dose increment, supplementary barrier contraception recommended. Increased vigilance on insulin and sulfonylureas (potentiated hypoglycemia despite glucagon balance).

06Can retatrutide be combined with other research peptides (BPC-157, TB-500, CJC-1295, ipamorelin)?

Combinations are explored in advanced research contexts. BPC-157 and TB-500 (healing and tissue repair) are pharmacodynamically orthogonal to retatrutide, no interaction expected. CJC-1295 + ipamorelin (GH/IGF-1 stimulation) can potentiate certain metabolic effects and require enhanced glycemic monitoring, especially given the retatrutide glucagon arm which may add to the gluconeogenic effect of the GH axis. No direct pharmacokinetic interaction expected (retatrutide proteolytic clearance, no CYP450). In exploratory research, documenting each combination and observed effects is essential to exploit data value.

07Which format should I choose for a long cohort protocol (16+ weeks) at 12mg/week?

For 16 weeks at 12mg/week, total need 192mg. Options: 20mg format yields 10 reconstitutions (1.67 weeks coverage per vial, tight stability margin); 30mg format yields 7 reconstitutions (2.5 weeks per vial, comfortable margin); 40mg format yields 5 reconstitutions (3.3 weeks per vial, very comfortable margin). For 24 weeks at 12mg/w, need 288mg: 40mg format = 8 reconstitutions (optimal margin). 30mg and 40mg are the formats of choice for long cycles. 5mg and 10mg target initial titration (before reaching the 12mg plateau), and 15mg/20mg for intermediate 4-8 week cycles.

08Why should retatrutide never be mixed with insulin or another peptide in the same syringe?

Retatrutide formulations include a phosphate/citrate buffer and excipients (phenol, methionine antioxidant) calibrated for its stability. Mixing with insulin (pH varying by type) causes precipitation, C20 chain oligomerization, and activity loss. Mixing with another peptide (BPC-157, TB-500, CJC-1295) triggers hydrophobic interactions between acylated chains (C20 vs other esters) and cross-degradation. In research, always administer as separate injections: different sites, fresh syringes, minutes apart to isolate kinetics and cleanly document each agent's effects. This discipline is particularly critical for retatrutide whose triple agonism already complicates experimental analysis.

Benchmark

Similar peptides

Versus tirzepatide (GLP-1/GIP dual agonist): retatrutide surpasses tirzepatide in documented weight efficacy. Phase II Jastreboff 2023 NEJM: -24.2% at 12mg/48w for retatrutide vs SURMOUNT-1 Jastreboff 2022: -20.9% at 15mg/72w for tirzepatide. The absolute 3.3-point weight gap over a shorter window (48 vs 72 weeks) suggests retatrutide reaches maximum plateau faster and further. The GCGR arm adds hepatic thermogenesis and lipolysis that tirzepatide does not generate. Limit: retatrutide is newer, with fewer long-term data (phase III ongoing, not yet published), and the glucagon arm imposes stricter ALT/AST follow-up.

Versus semaglutide (GLP-1 mono-agonist): considerable gap. STEP-1 Wilding 2021 NEJM: -14.9% at 2.4mg/68w for semaglutide vs -24.2% at 12mg/48w for retatrutide. For a researcher seeking maximal metabolic performance, retatrutide is superior by >9 weight points over a shorter window. Semaglutide remains the option when gastrointestinal tolerance is problematic (milder profile) or on tight budget (older molecule, available in more economical formats).

Versus liraglutide 3mg (Saxenda): massive gap (-8% over 56 weeks Pi-Sunyer 2015 NEJM SCALE vs -24.2% over 48 weeks for retatrutide). Liraglutide is outpaced by all modern incretin agents and holds residual interest only for its long-term data (> 5 years) which retatrutide still lacks.

Versus bariatric surgery (sleeve, Roux-en-Y bypass): the most strategically interesting comparison. Sleeve typically produces -25% at 1 year, bypass -30-35%. Retatrutide 12mg produced -24.2% at 48 weeks (phase II) and could reach -28-30% at 72 weeks by extrapolation (TRIUMPH phase III results pending). For the first time, a non-invasive pharmacological agent approaches or exceeds the least aggressive bariatric surgery. Limit: weight regain is faster upon drug discontinuation than after surgery, and cumulative chronic treatment cost may equal or exceed surgery at 5-7 years.

Versus other triple/multi-agonists in development: survodutide (GLP-1/GCGR Boehringer Ingelheim), mazdutide (GLP-1/GCGR Eli Lilly), orforglipron (oral non-peptide GLP-1 Eli Lilly), HRS9531 (GLP-1/GIP Hengrui): each represents a distinct signaling architecture. Retatrutide remains the most advanced triple agonist in phase III and holds the highest published weight efficacy to date.

Versus bupropion-naltrexone, orlistat, phentermine-topiramate: the gap is such that these agents no longer compete. They remain relevant as inexpensive oral alternatives for patients refusing injection or with incretin contraindications.

Research positioning: retatrutide is the most powerful tool currently available to study multi-receptor metabolic regulation. Its triple agonism allows simultaneous study of combined GLP-1 + GIP + glucagon effects, experimental dissections impossible with mono-agonists or dual agonists. Exploratory protocols thus gain unique signaling benefit at the cost of more demanding monitoring complexity.

Full guide: Retatrutide — mechanism, studies, dose comparison

Retatrutide 40mg Weight Loss

Metabolism

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Metabolism

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents